BR112014008819A8 - Métodos para o tratamento de síndrome de vazamento vascular e câncer - Google Patents
Métodos para o tratamento de síndrome de vazamento vascular e câncerInfo
- Publication number
- BR112014008819A8 BR112014008819A8 BR112014008819A BR112014008819A BR112014008819A8 BR 112014008819 A8 BR112014008819 A8 BR 112014008819A8 BR 112014008819 A BR112014008819 A BR 112014008819A BR 112014008819 A BR112014008819 A BR 112014008819A BR 112014008819 A8 BR112014008819 A8 BR 112014008819A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- cancer
- treatment
- leak syndrome
- vascular leak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
Abstract
MÉTODOS PARA O TRATAMENTO DE SÍNDROME DE VAZAMENTO VASCULAR E CÂNCER. São divulgados métodos para tratamento de síndrome de vazamento vascular e prevenção da metástase do câncer. São ainda divulgados métodos para o tratamento de vazamento vascular devido a doenças inflamatórias, sepse, câncer ou a presença de agentes patogênicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546748P | 2011-10-13 | 2011-10-13 | |
US201161546697P | 2011-10-13 | 2011-10-13 | |
PCT/US2012/060273 WO2013056240A1 (en) | 2011-10-13 | 2012-10-15 | Methods for treating vascular leak syndrome and cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014008819A2 BR112014008819A2 (pt) | 2017-06-13 |
BR112014008819A8 true BR112014008819A8 (pt) | 2017-09-12 |
Family
ID=48082581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014008819A BR112014008819A8 (pt) | 2011-10-13 | 2012-10-15 | Métodos para o tratamento de síndrome de vazamento vascular e câncer |
Country Status (10)
Country | Link |
---|---|
US (4) | US20130095065A1 (pt) |
EP (2) | EP2766043A4 (pt) |
JP (5) | JP2014530244A (pt) |
CN (1) | CN104039351A (pt) |
AU (1) | AU2012323856B2 (pt) |
BR (1) | BR112014008819A8 (pt) |
CA (1) | CA2850830A1 (pt) |
HK (1) | HK1201178A1 (pt) |
MX (2) | MX363351B (pt) |
WO (1) | WO2013056240A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SMP200800060B (it) | 2006-04-07 | 2009-07-14 | Procter & Gamble | Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US9096555B2 (en) * | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
RU2521251C2 (ru) | 2009-11-06 | 2014-06-27 | Аэрпио Терапьютикс Инк. | Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа |
US8999325B2 (en) | 2011-10-13 | 2015-04-07 | Aerpio Therapeutics, Inc | Treatment of ocular disease |
WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
EP3607821B1 (en) | 2013-03-15 | 2022-08-03 | EyePoint Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US9828422B2 (en) | 2013-07-29 | 2017-11-28 | Samsung Electronics Co., Ltd. | Anti-Ang2 antibody |
KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
JP6549140B2 (ja) | 2014-02-19 | 2019-07-24 | エアーピオ セラピューティクス インコーポレイテッド | N−ベンジル−3−ヒドロキシ−4−置換ピリジン−2−(1h)−オン |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
WO2016196774A1 (en) * | 2015-06-03 | 2016-12-08 | Aelan Cell Technologies, Inc. | Methods and devices for the production and delivery of beneficial factors from stem cells |
EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
AU2017299581A1 (en) | 2016-07-20 | 2019-01-17 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
CA3052474A1 (en) | 2017-02-09 | 2018-08-16 | Fred Hutchinson Cancer Research Center | Biomarkers and uses thereof for selecting immunotherapy intervention |
US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
EP3962466A4 (en) * | 2019-05-02 | 2023-01-25 | Biogen Chesapeake LLC | METHODS OF TREATMENT OF PERSONS WITH CONtusions Of The Central Nervous System |
US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
CA2216963C (en) | 1995-04-06 | 2010-06-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
AU5154098A (en) | 1996-10-31 | 1998-05-22 | Duke University | Soluble tie2 receptor |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
DK1165115T3 (da) | 1999-03-26 | 2003-09-22 | Regeneron Pharma | Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer |
EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
HUP0302779A3 (en) | 2000-06-23 | 2005-12-28 | Schering Ag | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
US6316109B1 (en) | 2000-09-21 | 2001-11-13 | Ppg Industries Ohio, Inc. | Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers |
KR20040039428A (ko) | 2001-09-28 | 2004-05-10 | 산텐 세이야꾸 가부시키가이샤 | 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제 |
AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
US20030158083A1 (en) | 2002-02-08 | 2003-08-21 | The Procter & Gamble Company | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase |
WO2003084565A2 (en) | 2002-04-08 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
IL164799A0 (en) | 2002-04-25 | 2005-12-18 | Univ Connecticut | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7718377B2 (en) | 2003-05-29 | 2010-05-18 | Kyoto Pharmaceutical Industries, Ltd. | Insulin resistance curative and method of screening the same |
AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
SI1725537T1 (sl) | 2004-03-15 | 2011-11-30 | Janssen Pharmaceutica Nv | Nove spojine kot modulatorji opioidnih receptorjev |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
ZA200701183B (en) | 2004-07-20 | 2008-05-28 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, an their use |
KR100980693B1 (ko) | 2004-09-28 | 2010-09-07 | (주) 에이프로젠 | 꼬인 코일형 키메라분자를 유효성분으로 하는 발기부전 치료제 |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
WO2007068895A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
PL2596807T3 (pl) | 2006-03-08 | 2016-06-30 | Archemix Llc | Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych |
CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
SMP200800060B (it) | 2006-04-07 | 2009-07-14 | Procter & Gamble | Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
PT2076290T (pt) | 2006-10-27 | 2017-01-17 | Sunnybrook Health Sciences Center | Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
WO2008127727A1 (en) | 2007-04-13 | 2008-10-23 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
US8319703B2 (en) * | 2007-06-28 | 2012-11-27 | Qualcomm Mems Technologies, Inc. | Rendering an image pixel in a composite display |
CN101802011A (zh) | 2007-06-29 | 2010-08-11 | 先灵公司 | Mdl-1应用 |
CN101918579A (zh) | 2007-10-22 | 2010-12-15 | 先灵公司 | 完全人抗-vegf抗体和使用方法 |
US9403789B2 (en) | 2008-02-21 | 2016-08-02 | Sequoia Pharmaceuticals, Inc. | Benzofuran-containing amino acid inhibitors of cytochrome P450 |
US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
RU2014146121A (ru) * | 2009-01-12 | 2015-06-10 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
KR20110130454A (ko) | 2009-03-03 | 2011-12-05 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(RTKi) 화합물을 눈에 전달하기 위한 약학 조성물 |
WO2010101971A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
RU2521251C2 (ru) | 2009-11-06 | 2014-06-27 | Аэрпио Терапьютикс Инк. | Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа |
CN102711756A (zh) * | 2010-01-14 | 2012-10-03 | 株式会社三和化学研究所 | 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物 |
CA2803675A1 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
KR101823924B1 (ko) | 2010-10-07 | 2018-01-31 | 에르피오 세러퓨틱스 인코포레이티드 | 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법 |
US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
EP2857032A3 (en) | 2010-12-02 | 2015-07-15 | Maruzen Pharmaceuticals Co., Ltd. | Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition |
WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
US8999325B2 (en) | 2011-10-13 | 2015-04-07 | Aerpio Therapeutics, Inc | Treatment of ocular disease |
US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
WO2013155512A2 (en) | 2012-04-13 | 2013-10-17 | The Johns Hopkins University | Treatment of ischemic retinopathies |
KR102100093B1 (ko) | 2012-07-31 | 2020-05-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 췌장 베타 세포 형성의 생체내 유도를 위한 방법 및 조성물 |
JP2015533132A (ja) | 2012-10-11 | 2015-11-19 | アセンディス ファーマ オフサルモロジー ディヴィジョン エー/エス | 眼状態を処置するためのvegf中和プロドラッグ |
KR20150083117A (ko) | 2012-11-08 | 2015-07-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
US20150290235A1 (en) | 2012-11-23 | 2015-10-15 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
EP3607821B1 (en) | 2013-03-15 | 2022-08-03 | EyePoint Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
CA2909080C (en) | 2013-04-11 | 2022-07-26 | Sunnybrook Research Institute | Methods, uses and compositions of tie2 agonists |
JP2016522250A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 黄斑浮腫の治療におけるvegfアンタゴニストの使用 |
JP2016522249A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるvegfアンタゴニストの使用 |
WO2015002893A1 (en) | 2013-07-02 | 2015-01-08 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
CN105377891A (zh) | 2013-07-11 | 2016-03-02 | 诺华股份有限公司 | Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 |
MX2016000385A (es) | 2013-07-11 | 2016-04-29 | Novartis Ag | Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. |
US9828422B2 (en) | 2013-07-29 | 2017-11-28 | Samsung Electronics Co., Ltd. | Anti-Ang2 antibody |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
TR201905773T4 (tr) | 2013-10-01 | 2019-05-21 | Sphingotec Gmbh | Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul. |
US9592271B2 (en) | 2013-11-01 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
WO2015152416A1 (ja) | 2014-04-04 | 2015-10-08 | 国立大学法人東北大学 | 眼圧降下剤 |
US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
AU2017299581A1 (en) | 2016-07-20 | 2019-01-17 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
-
2012
- 2012-10-15 WO PCT/US2012/060273 patent/WO2013056240A1/en active Application Filing
- 2012-10-15 AU AU2012323856A patent/AU2012323856B2/en active Active
- 2012-10-15 US US13/652,203 patent/US20130095065A1/en not_active Abandoned
- 2012-10-15 BR BR112014008819A patent/BR112014008819A8/pt not_active Application Discontinuation
- 2012-10-15 JP JP2014535979A patent/JP2014530244A/ja not_active Withdrawn
- 2012-10-15 CA CA2850830A patent/CA2850830A1/en not_active Abandoned
- 2012-10-15 CN CN201280052307.5A patent/CN104039351A/zh active Pending
- 2012-10-15 EP EP12840220.3A patent/EP2766043A4/en not_active Withdrawn
- 2012-10-15 MX MX2014004448A patent/MX363351B/es unknown
- 2012-10-15 EP EP18201774.9A patent/EP3505182A1/en active Pending
-
2014
- 2014-04-11 MX MX2019002983A patent/MX2019002983A/es unknown
-
2015
- 2015-02-13 HK HK15101641.4A patent/HK1201178A1/xx unknown
-
2017
- 2017-02-21 US US15/438,218 patent/US10150811B2/en active Active
- 2017-07-03 JP JP2017130652A patent/JP2017165786A/ja not_active Withdrawn
- 2017-07-25 JP JP2017143622A patent/JP2017200947A/ja active Pending
-
2018
- 2018-10-23 US US16/168,060 patent/US10815300B2/en active Active
-
2019
- 2019-05-07 JP JP2019087483A patent/JP6706367B2/ja active Active
- 2019-06-21 JP JP2019115666A patent/JP2019151673A/ja not_active Withdrawn
-
2020
- 2020-09-21 US US17/027,034 patent/US20210095017A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2014530244A (ja) | 2014-11-17 |
JP2019151673A (ja) | 2019-09-12 |
US20180009890A1 (en) | 2018-01-11 |
EP2766043A4 (en) | 2015-06-10 |
JP2017165786A (ja) | 2017-09-21 |
JP2017200947A (ja) | 2017-11-09 |
US20190177409A1 (en) | 2019-06-13 |
MX2014004448A (es) | 2014-11-10 |
MX2019002983A (es) | 2023-04-12 |
US10815300B2 (en) | 2020-10-27 |
AU2012323856A1 (en) | 2014-04-17 |
CA2850830A1 (en) | 2013-04-18 |
EP2766043A1 (en) | 2014-08-20 |
CN104039351A (zh) | 2014-09-10 |
JP6706367B2 (ja) | 2020-06-03 |
EP3505182A1 (en) | 2019-07-03 |
MX363351B (es) | 2019-03-20 |
WO2013056240A1 (en) | 2013-04-18 |
JP2019151653A (ja) | 2019-09-12 |
BR112014008819A2 (pt) | 2017-06-13 |
US20130095065A1 (en) | 2013-04-18 |
AU2012323856B2 (en) | 2017-05-25 |
HK1201178A1 (en) | 2015-08-28 |
NZ623283A (en) | 2016-05-27 |
US20210095017A1 (en) | 2021-04-01 |
US10150811B2 (en) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014008819A8 (pt) | Métodos para o tratamento de síndrome de vazamento vascular e câncer | |
WO2014089241A3 (en) | Molecular profiling for cancer | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
UY34218A (es) | MÉTODO DE DETECCIÓN DEL EVENTO DE SOJA pDAB9582.814.19.1 | |
MX2015002947A (es) | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
EA201200998A1 (ru) | Способы лечения рака поджелудочной железы | |
EA201370071A1 (ru) | Способы и композиции для лечения рака легких | |
EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
EA201291386A1 (ru) | Стеклянное изделие с противомикробными свойствами | |
ECSP14011792A (es) | Inhibidores de iap | |
EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
EA201400996A1 (ru) | Комбинированная терапия для лечения рака яичника | |
EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
EA201301090A1 (ru) | Антидоты антикоагулянтов | |
IN2014DN08385A (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |